Entrada Therapeutics, Inc. (TRDA)
TRDA Stock Price Chart
Explore Entrada Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TRDA price movements and trends.
TRDA Company Profile
Discover essential business fundamentals and corporate details for Entrada Therapeutics, Inc. (TRDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Oct 2021
Employees
183.00
Website
https://www.entradatx.comCEO
Dipal Doshi
Description
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
TRDA Financial Timeline
Browse a chronological timeline of Entrada Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$1.05, while revenue estimate is $2.23m.
Earnings released on 7 May 2026
EPS came in at -$0.95 surpassing the estimated -$1.06 by +10.38%, while revenue for the quarter reached $875.00k , missing expectations by -70.03%.
Earnings released on 26 Feb 2026
EPS came in at -$0.94 surpassing the estimated -$1.32 by +28.79%, while revenue for the quarter reached $1.30m , missing expectations by -82.47%.
Earnings released on 6 Nov 2025
EPS came in at -$1.06 falling short of the estimated -$1.04 by -1.92%, while revenue for the quarter reached $1.61m , missing expectations by -80.99%.
Earnings released on 6 Aug 2025
EPS came in at -$1.04 falling short of the estimated -$0.86 by -20.93%, while revenue for the quarter reached $1.95m , missing expectations by -75.11%.
Earnings released on 8 May 2025
EPS came in at -$0.42 surpassing the estimated -$0.78 by +46.15%, while revenue for the quarter reached $20.56m , beating expectations by +110.40%.
Earnings released on 27 Feb 2025
EPS came in at $0.03 surpassing the estimated -$0.66 by +104.55%, while revenue for the quarter reached $37.40m , beating expectations by +185.04%.
Earnings released on 5 Nov 2024
EPS came in at -$0.35 surpassing the estimated -$0.67 by +47.76%, while revenue for the quarter reached $19.57m , beating expectations by +51.43%.
Earnings released on 13 Aug 2024
EPS came in at $1.55 surpassing the estimated $0.14 by +1.01k%, while revenue for the quarter reached $94.69m , beating expectations by +668.62%.
Earnings released on 7 May 2024
EPS came in at $0.68 surpassing the estimated -$0.59 by +215.25%, while revenue for the quarter reached $59.12m , beating expectations by +294.66%.
Earnings released on 13 Mar 2024
EPS came in at -$0.29 falling short of the estimated -$0.07 by -314.29%, while revenue for the quarter reached $41.85m , beating expectations by +76.65%.
Earnings released on 7 Nov 2023
EPS came in at $1.02 surpassing the estimated -$0.74 by +237.84%, while revenue for the quarter reached $43.74m , beating expectations by +104.27%.
Earnings released on 8 Aug 2023
EPS came in at -$0.78 falling short of the estimated -$0.43 by -81.40%, while revenue for the quarter reached $18.17m , beating expectations by +85.86%.
Earnings released on 10 May 2023
EPS came in at -$0.21 surpassing the estimated -$0.77 by +72.73%, while revenue for the quarter reached $25.26m , beating expectations by +158.28%.
Earnings released on 6 Mar 2023
EPS came in at -$0.79 surpassing the estimated -$0.84 by +5.95%.
Earnings released on 7 Nov 2022
EPS came in at -$0.80 falling short of the estimated -$0.76 by -5.26%.
Earnings released on 11 Aug 2022
EPS came in at -$0.74 falling short of the estimated -$0.72 by -2.78%.
Earnings released on 12 May 2022
EPS came in at -$0.69 falling short of the estimated -$0.65 by -6.15%.
Earnings released on 15 Mar 2022
EPS came in at -$0.89 surpassing the estimated -$1.28 by +30.47%.
Earnings released on 9 Dec 2021
EPS came in at -$9.78 falling short of the estimated -$0.87 by -1.02k%.
Earnings released on 1 Nov 2021
EPS came in at -$0.48 .
TRDA Stock Performance
Access detailed TRDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
